Ethical challenges of clinical trials with a repurposed drug in outbreaks

[1]  J. Kimmelman,et al.  Competition for recruitment in SARS-CoV-2 Trials in the United States: a longitudinal cohort analysis , 2022, BMC research notes.

[2]  Mariusz Maziarz,et al.  The failure of drug repurposing for COVID-19 as an effect of excessive hypothesis testing and weak mechanistic evidence , 2022, History and Philosophy of the Life Sciences.

[3]  Lada Leyens,et al.  The COVID-19 pandemic as a catalyst for innovation: a regulatory framework to assess fit-for-purpose innovative approaches in clinical research , 2022, Trials.

[4]  L. Guizzaro,et al.  The Impact of COVID‐19 on the Initiation of Clinical Trials in Europe and the United States , 2022, Clinical pharmacology and therapeutics.

[5]  M. G. Jeppesen,et al.  Author Correction: Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro , 2021, Communications Biology.

[6]  M. G. Jeppesen,et al.  Amantadine inhibits known and novel ion channels encoded by SARS-CoV-2 in vitro , 2021, Communications Biology.

[7]  C. Yap,et al.  Implementation of platform trials in the COVID-19 pandemic: A rapid review , 2021, Contemporary Clinical Trials.

[8]  A. Caplan,et al.  Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases? , 2021, The American journal of bioethics : AJOB.

[9]  J. Al-Hashel,et al.  Effect of Pre-exposure Use of Amantadine on COVID-19 Infection: A Hospital-Based Cohort Study in Patients With Parkinson's Disease or Multiple Sclerosis , 2021, Frontiers in Neurology.

[10]  J. Bukh,et al.  Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro , 2021, Viruses.

[11]  J. Baell,et al.  Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers , 2021, Science Translational Medicine.

[12]  J. Kimmelman,et al.  How informative were early SARS-CoV-2 treatment and prevention trials? a longitudinal cohort analysis of trials registered on ClinicalTrials.gov , 2021, medRxiv.

[13]  P. Venkatesan.  Repurposing drugs for treatment of COVID-19 , 2021, The Lancet Respiratory Medicine.

[14]  D. Sahoo,et al.  Drug repurposing screens identify chemical entities for the development of COVID-19 interventions , 2021, Nature Communications.

[15]  G. Aranda-Abreu,et al.  The efficacy of amantadine hydrochloride in the treatment of COVID-19 - a single-center observation study. , 2021, Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego.

[16]  I. Rooman,et al.  Exploring new uses for existing drugs: innovative mechanisms to fund independent clinical research , 2021, Trials.

[17]  Jay J H Park,et al.  How COVID-19 has fundamentally changed clinical research in global health , 2021, The Lancet Global Health.

[18]  W. Danysz,et al.  Amantadine Inhibits SARS-CoV-2 In Vitro , 2021, Viruses.

[19]  J. Ioannidis,et al.  Challenges and Lessons Learned From COVID-19 Trials: Should We Be Doing Clinical Trials Differently? , 2021, Canadian Journal of Cardiology.

[20]  B. Sahoo,et al.  Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection , 2021, Frontiers in Molecular Biosciences.

[21]  B. Wilfond,et al.  An ethics framework for consolidating and prioritizing COVID-19 clinical trials , 2021, Clinical trials.

[22]  Nina S. Hsu,et al.  Ethical considerations of COVID-19-related adjustments to clinical research , 2021, Nature Medicine.

[23]  Julian Matschinske,et al.  Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies , 2021, Nature Computational Science.

[24]  T. Bubela,et al.  Let’s Do Better: Public Representations of COVID-19 Science , 2020 .

[25]  Daria Kim,et al.  Redundant trials can be prevented, if the EU clinical trial regulation is applied duly , 2020, BMC medical ethics.

[26]  A. Kesselheim,et al.  Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19 , 2020, BMJ.

[27]  J. Mancilla-Galindo,et al.  Use of antivirals and antibiotics for COVID-19 in Mexico City: A Real-World Multicenter Cohort Study , 2020, medRxiv.

[28]  M. Hernández-Aguilar,et al.  Observational study of people infected with SARS-Cov-2, treated with amantadine , 2020, Pharmacological Reports.

[29]  Gillian Ferry,et al.  It is unprecedented: trial management during the COVID-19 pandemic and beyond , 2020, Trials.

[30]  Martin A. Tanner,et al.  Forecasting for COVID-19 has failed , 2020, International Journal of Forecasting.

[31]  S. Chanda,et al.  Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing , 2020, Nature.

[32]  Eytan Ruppin,et al.  Discovery of SARS-CoV-2 Antivirals through Large-scale Drug Repositioning , 2020, Nature.

[33]  G. Aranda-Abreu,et al.  Use of amantadine in a patient with SARS‐CoV‐2 , 2020, Journal of medical virology.

[34]  A. Cortés Borra.  Does amantadine have a protective effect against COVID-19? , 2020, Neurologia i neurochirurgia polska.

[35]  Tracey Williams,et al.  The impact of COVID-19 , 2020, Journal of perioperative practice.

[36]  Konrad Rejdak,et al.  Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment , 2020, Multiple Sclerosis and Related Disorders.

[37]  M. Polymeropoulos,et al.  Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment , 2020, International Journal of Antimicrobial Agents.

[38]  Gonzalo Emiliano Aranda Abreu,et al.  Amantadine as a drug to mitigate the effects of COVID-19 , 2020, Medical Hypotheses.

[39]  Ross Upshur,et al.  Panic prescribing has become omnipresent during the COVID-19 pandemic. , 2020, The Journal of clinical investigation.

[40]  Alex John London,et al.  Against pandemic research exceptionalism , 2020, Science.

[41]  D. Strech,et al.  Results dissemination of registered clinical trials across Polish academic institutions: a cross-sectional analysis , 2020, BMJ Open.

[42]  Taha Nisar,et al.  Antiviral amantadine , 2019, The Lancet Neurology.

[43]  Vivek Gupta,et al.  Drug repurposing: a promising tool to accelerate the drug discovery process. , 2019, Drug discovery today.

[44]  B. Strom,et al.  Trends in Off-Label Drug Use in Ambulatory Settings: 2006–2015 , 2019, Pediatrics.

[45]  S. Goodman,et al.  Harms From Uninformative Clinical Trials. , 2019, JAMA.

[46]  P. Sanseau,et al.  Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.

[47]  J. Locascio,et al.  Randomised controlled trials – the gold standard for effectiveness research , 2018, BJOG : an international journal of obstetrics and gynaecology.

[48]  L. Chew,et al.  Off‐label drug use in oncology: a systematic review of literature , 2017, Journal of clinical pharmacy and therapeutics.

[49]  D. Wendler,et al.  In Defense of a Social Value Requirement for Clinical Research , 2017, Bioethics.

[50]  Rieke van der Graaf,et al.  International Ethical Guidelines for Health-related Research involving Humans , 2017 .

[51]  J. V. van Delden,et al.  What do international ethics guidelines say in terms of the scope of medical research ethics? , 2016, BMC medical ethics.

[52]  J. Connor,et al.  The platform trial: an efficient strategy for evaluating multiple treatments. , 2015, JAMA.

[53]  V. Rajadhyaksha.  Conducting Feasibilities in Clinical Trials: An Investment to Ensure a Good Study , 2010, Perspectives in clinical research.

[54]  R. Dooling,et al.  MASKING , 2008, The SAGE Encyclopedia of Research Design.

[55]  T. Ashburn,et al.  Drug repositioning: identifying and developing new uses for existing drugs , 2004, Nature Reviews Drug Discovery.

[56]  J. Hanley,et al.  Association of Off-label Drug Use and Adverse Drug Events in an Adult Population. , 2016, JAMA internal medicine.

[57]  P. Leung.  An ethics framework , 2005 .